Palatin Technologies' Bremelanotide - Competition and regulatory risk cloud potential

Questions: Discounts, Updates etc.

Price: $3,800.00

Publication Date: 2006-09-06

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Palatin Technologies' bremelanotide (PT-141) is a novel melanocortin receptor agonist that is believed to be the only agent currently in development for the treatment of both erectile dysfunction (ED) and female sexual dysfunction (FSD).


Scope

  • Explores the regulatory and commercial potential for PTN's bremelanotide, a novel agent in development for male and female sexual dysfunction
  • Interviews with 7 urologists familiar with bremelanotide and its clinical data and potential for the treatment of male and female sexual dysfunction


    • Report Highlights
    While there would appear to be much potential for an agent that can improve libido in both male and female patients without acting directly on the vascular system, we believe that unclear efficacy of PTN's bremelanotide and substantial regulatory risk diminish the potential this agent in the treatment of male and female sexual dysfunction.

    Pending results from the two Phase IIb trials which are expected later this year, we forecast US bremelanotide revenues well below the blockbuster potential estimated by some Wall Street analysts.


    Reasons to Purchase

  • Understand the commercial potential for Palatin Technologies' Bremelanotide through in-depth analysis based on interviews with leading experts
  • Anticipate likely changes in the future market dynamics for erectile dysfunction therapies if approval of bremelanotide occurs

    • Table of Contents

    Other users found this report page using the following search terms: palatin Bremelanotide Melanocortin sexual bremelanotide palatin technologies dysfunction erectile price models updates pdf cloud

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.